IgG4相关肝胆胰疾病诊疗进展

王天琪; 刘燕鹰

doi:10.3969/j.issn.1001-5256.2022.04.006

IgG4相关肝胆胰疾病诊疗进展

DOI: 10.3969/j.issn.1001-5256.2022.04.006

王天琪,
刘燕鹰^, ,

首都医科大学附属北京友谊医院风湿内科，北京 100050

基金项目:

首都卫生发展科研专项 (2022-2-2026)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：王天琪负责文献检索、撰写文章；刘燕鹰负责文章的整体指导、审核及修改完善。

详细信息

通信作者:
刘燕鹰，57495011@qq.com

计量
- 文章访问数: 738
- HTML全文浏览量: 158
- PDF下载量: 149
- 被引次数: 0
出版历程
- 收稿日期: 2022-01-11
- 录用日期: 2022-02-13
- 出版日期: 2022-04-20

Advances in diagnosis and treatment of IgG4-related hepatobiliary and pancreatic diseases

Tianqi WANG,
Yanying LIU^{,
,}

Department of Rheumatology and Immunology, Beijing Friendship Hospital, Captital Medical University, Beijing 100050, China

Research funding:

Capital's Fund for Healthy Improvement and Researth (2022-2-2026)

More Information

Corresponding author: LIU Yanying, 57495011@qq.com(ORCID: 0000-0003-2609-4052)

摘要

摘要: IgG4相关肝胆胰疾病是IgG4相关疾病多器官纤维化炎性疾病的一部分，包括IgG4相关自身免疫性胰腺炎、IgG4相关硬化性胆管炎、IgG4相关肝脏病变。主要病理表现为IgG4⁺浆细胞、淋巴细胞浸润，伴有席纹状纤维化、闭塞性静脉炎和嗜酸性粒细胞浸润。临床诊断多采用IgG4相关疾病综合诊断标准和专科制定的特异性器官受累诊断标准，难点在于与肿瘤性疾病的鉴别，新型诊断标志物有望提高诊断敏感度及特异度。迄今，一线治疗药物仍为糖皮质激素，生物制剂，尤其是CD20单抗疗效肯定，对于激素禁忌/不耐受或复发难治性患者不失为一种选择。
- IgG4相关疾病 /
- 胰腺炎 /
- 胆管炎, 硬化性 /
- 肝疾病
Abstract: IgG4-related hepatobiliary and pancreatic diseases are a part of the IgG4-related disease multiorgan fibroinflammatory disorder, including IgG4-related autoimmune pancreatitis, IgG4-related sclerosing cholangitis, and IgG4-related hepatic involvement. The main pathological features include IgG4⁺ plasma cell/lymphocyte infiltration, storiform fibrosis, obliterative phlebitis, and eosinophil infiltration. The diagnosis of this disease is often based on the comprehensive diagnostic criteria for IgG4-related diseases and organ-specific diagnostic criteria. However, it is difficult to differentiate IgG4-related hepatobiliary and pancreatic diseases from neoplastic diseases, and novel diagnostic biomarkers are expected to improve the sensitivity and specificity of diagnosis. To date, glucocorticoids remain the first-line drug for this disease, and biological agents, especially anti-CD20 monoclonal antibody, may be an alternative therapy for patients with corticosteroid contraindication/intolerance or recurrent/refractory disease.
- IgG4-Related Diseases /
- Pancreatitis /
- Cholangitis, Sclerosing /
- Liver Diseases

HTML全文

参考文献(46)

[1]	KAMISAWA T, EGAWA N, NAKAJIMA H. Autoimmune pancreatitis is a systemic autoimmune disease[J]. Am J Gastroenterol, 2003, 98(12): 2811-2812. DOI: 10.1111/j.1572-0241.2003.08758.x.
[2]	WALLACE ZS, ZHANG Y, PERUGINO CA, et al. Clinical phenotypes of IgG4-related disease: An analysis of two international cross-sectional cohorts[J]. Ann Rheum Dis, 2019, 78(3): 406-412. DOI: 10.1136/annrheumdis-2018-214603.
[3]	LIU Y, XUE M, WANG Z, et al. Salivary gland involvement disparities in clinical characteristics of IgG4-related disease: A retrospective study of 428 patients[J]. Rheumatology (Oxford), 2020, 59(3): 634-640. DOI: 10.1093/rheumatology/kez280.
[4]	LANZILLOTTA M, CAMPOCHIARO C, MANCUSO G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes[J]. Rheumatology (Oxford), 2020, 59(9): 2435-2442. DOI: 10.1093/rheumatology/keaa221.
[5]	DELLA-TORRE E, MANCUSO G, LANZILLOTTA M, et al. Urgent manifestations of immunoglobulin G4-related disease[J]. Scand J Rheumatol, 2021, 50(1): 48-51. DOI: 10.1080/03009742.2020.1771763.
[6]	GHAZALE A, CHARI ST, ZHANG L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy[J]. Gastroenterology, 2008, 134(3): 706-715. DOI: 10.1053/j.gastro.2007.12.009.
[7]	TANAKA A, TAZUMA S, OKAZAKI K, et al. Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis[J]. Clin Gastroenterol Hepatol, 2017, 15(6): 920-926.e3. DOI: 10.1016/j.cgh.2016.12.038.
[8]	KAMISAWA T, EGAWA N, NAKAJIMA H, et al. Extrapancreatic lesions in autoimmune pancreatitis[J]. J Clin Gastroenterol, 2005, 39(10): 904-907. DOI: 10.1097/01.mcg.0000180629.77066.6c.
[9]	XU WL, LING YC, WANG ZK, et al. Diagnostic performance of serum IgG4 level for IgG4-related disease: A meta-analysis[J]. Sci Rep, 2016, 6: 32035. DOI: 10.1038/srep32035.
[10]	YAMADA K, YAMAMOTO M, SAEKI T, et al. New clues to the nature of immunoglobulin G4-related disease: A retrospective Japanese multicenter study of baseline clinical features of 334 cases[J]. Arthritis Res Ther, 2017, 19(1): 262. DOI: 10.1186/s13075-017-1467-x.
[11]	BOONSTRA K, CULVER EL, DE BUY WENNIGER LM, et al. Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis[J]. Hepatology, 2014, 59(5): 1954-1963. DOI: 10.1002/hep.26977.
[12]	OSEINI AM, CHAITEERAKIJ R, SHIRE AM, et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma[J]. Hepatology, 2011, 54(3): 940-948. DOI: 10.1002/hep.24487.
[13]	OHARA H, NAKAZAWA T, KAWA S, et al. Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis: A Japanese cohort[J]. J Gastroenterol Hepatol, 2013, 28(7): 1247-1251. DOI: 10.1111/jgh.12248.
[14]	KAMISAWA T, SHIMOSEGAWA T, OKAZAKI K, et al. Standard steroid treatment for autoimmune pancreatitis[J]. Gut, 2009, 58(11): 1504-1507. DOI: 10.1136/gut.2008.172908.
[15]	WALLACE ZS, DESHPANDE V, MATTOO H, et al. IgG4-related disease: Clinical and laboratory features in one hundred twenty-five patients[J]. Arthritis Rheumatol, 2015, 67(9): 2466-2475. DOI: 10.1002/art.39205.
[16]	DELLA TORRE E, MATTOO H, MAHAJAN VS, et al. Prevalence of atopy, eosinophilia, and IgE elevation in IgG4-related disease[J]. Allergy, 2014, 69(2): 269-272. DOI: 10.1111/all.12320.
[17]	CULVER EL, BARNES E. IgG4-related sclerosing cholangitis[J]. Clin Liver Dis (Hoboken), 2017, 10(1): 9-16. DOI: 10.1002/cld.642.
[18]	YU KH, CHAN TM, TSAI PH, et al. Diagnostic performance of serum IgG4 levels in patients with IgG4-related disease[J]. Medicine (Baltimore), 2015, 94(41): e1707. DOI: 10.1097/MD.0000000000001707.
[19]	DOORENSPLEET ME, HUBERS LM, CULVER EL, et al. Immunoglobulin G4(+) B-cell receptor clones distinguish immunoglobulin G4-related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies[J]. Hepatology, 2016, 64(2): 501-507. DOI: 10.1002/hep.28568.
[20]	LANZILLOTTA M, DELLA-TORRE E, MILANI R, et al. Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease[J]. Clin Exp Rheumatol, 2019, 37 Suppl 118(3): 159-166.
[21]	ITO T, TANAKA T, NAKAMARU K, et al. Interleukin-35 promotes the differentiation of regulatory T cells and suppresses Th2 response in IgG4-related type 1 autoimmune pancreatitis[J]. J Gastroenterol, 2020, 55(8): 789-799. DOI: 10.1007/s00535-020-01689-5.
[22]	ZHANG J, LIAN M, LI B, et al. Interleukin-35 promotes Th9 cell differentiation in IgG4-related disorders: Experimental data and review of the literature[J]. Clin Rev Allergy Immunol, 2021, 60(1): 132-145. DOI: 10.1007/s12016-020-08803-8.
[23]	MINAGA K, WATANABE T, HARA A, et al. Identification of serum IFN-α and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease[J]. Sci Rep, 2020, 10(1): 14879. DOI: 10.1038/s41598-020-71848-4.
[24]	ZEN Y, LIBERAL R, NAKANUMA Y, et al. Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis[J]. J Hepatol, 2013, 59(5): 1059-1064. DOI: 10.1016/j.jhep.2013.06.016.
[25]	FUJⅡ-LAU LL, LEVY MJ. The role of endoscopic ultrasound in the diagnosis of autoimmune pancreatitis[J]. Gastrointest Endosc Clin N Am, 2017, 27(4): 643-655. DOI: 10.1016/j.giec.2017.06.005.
[26]	TOKALA A, KHALILI K, MENEZES R, et al. Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis[J]. AJR Am J Roentgenol, 2014, 202(3): 536-543. DOI: 10.2214/AJR.12.10360.
[27]	NAKAZAWA T, SHIMIZU S, NAITOH I. IgG4-related sclerosing cholangitis[J]. Semin Liver Dis, 2016, 36(3): 216-228. DOI: 10.1055/s-0036-1584321.
[28]	TABATA T, KAMISAWA T, HARA S, et al. Differentiating immunoglobulin g4-related sclerosing cholangitis from hilar cholangiocarcinoma[J]. Gut Liver, 2013, 7(2): 234-238. DOI: 10.5009/gnl.2013.7.2.234.
[29]	KALAITZAKIS E, LEVY M, KAMISAWA T, et al. Endoscopic retrograde cholangiography does not reliably distinguish IgG4-associated cholangitis from primary sclerosing cholangitis or cholangiocarcinoma[J]. Clin Gastroenterol Hepatol, 2011, 9(9): 800-803.e2. DOI: 10.1016/j.cgh.2011.05.019.
[30]	ARORA K, RIVERA M, TING DT, et al. The histological diagnosis of IgG4-related disease on small biopsies: Challenges and pitfalls[J]. Histopathology, 2019, 74(5): 688-698. DOI: 10.1111/his.13787.
[31]	ZEN Y, FUJⅡ T, SATO Y, et al. Pathological classification of hepatic inflammatory pseudotumor with respect to IgG4-related disease[J]. Mod Pathol, 2007, 20(8): 884-894. DOI: 10.1038/modpathol.3800836.
[32]	UMEHARA H, OKAZAKI K, KAWA S, et al. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD[J]. Mod Rheumatol, 2021, 31(3): 529-533. DOI: 10.1080/14397595.2020.1859710.
[33]	WALLACE ZS, NADEN RP, CHARI S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease[J]. Ann Rheum Dis, 2020, 79(1): 77-87. DOI: 10.1136/annrheumdis-2019-216561.
[34]	KAWA S, KAMISAWA T, NOTOHARA K, et al. Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2018: Revision of Japanese clinical diagnostic criteria for autoimmune pancreatitis, 2011[J]. Pancreas, 2020, 49(1): e13-e14. DOI: 10.1097/MPA.0000000000001443.
[35]	NAKAZAWA T, KAMISAWA T, OKAZAKI K, et al. Clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2020: (Revision of the clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2012)[J]. J Hepatobiliary Pancreat Sci, 2021, 28(3): 235-242. DOI: 10.1002/jhbp.913.
[36]	NAKANUMA Y, ISHIZU Y, ZEN Y, et al. Histopathology of IgG4-related autoimmune hepatitis and IgG4-related hepatopathy in igg4-related disease[J]. Semin Liver Dis, 2016, 36(3): 229-241. DOI: 10.1055/s-0036-1584320.
[37]	KURAISHI Y, UEHARA T, WATANABE T, et al. Corticosteroids prevent the progression of autoimmune pancreatitis to chronic pancreatitis[J]. Pancreatology, 2020, 20(6): 1062-1068. DOI: 10.1016/j.pan.2020.07.408.
[38]	BARRESI L, TACELLI M, CRINÒ SF, et al. Multicentric Italian survey on daily practice for autoimmune pancreatitis: Clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency[J]. United European Gastroenterol J, 2020, 8(6): 705-715. DOI: 10.1177/2050640620924302.
[39]	OKAZAKI K, CHARI ST, FRULLONI L, et al. International consensus for the treatment of autoimmune pancreatitis[J]. Pancreatology, 2017, 17(1): 1-6. DOI: 10.1016/j.pan.2016.12.003.
[40]	KHANDELWAL A, INOUE D, TAKAHASHI N. Autoimmune pancreatitis: An update[J]. Abdom Radiol (NY), 2020, 45(5): 1359-1370. DOI: 10.1007/s00261-019-02275-x.
[41]	HART PA, TOPAZIAN MD, WITZIG TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: The Mayo Clinic experience[J]. Gut, 2013, 62(11): 1607-1615. DOI: 10.1136/gutjnl-2012-302886.
[42]	DU S, LIU G, CHENG X, et al. Differential diagnosis of immunoglobulin G4-associated cholangitis from cholangiocarcinoma[J]. J Clin Gastroenterol, 2016, 50(6): 501-505. DOI: 10.1097/MCG.0000000000000509.
[43]	LANZILLOTTA M, VINGE-HOLMQUIST O, OVERBEEK KA, et al. PrescrAIP: A Pan-European study on current treatment regimens of auto-immune pancreatitis[J]. Front Med (Lausanne), 2020, 7: 408. DOI: 10.3389/fmed.2020.00408.
[44]	TACELLI M, CELSA C, MAGRO B, et al. Risk factors for rate of relapse and effects of steroid maintenance therapy in patients with autoimmune pancreatitis: Systematic review and Meta-analysis[J]. Clin Gastroenterol Hepatol, 2019, 17(6): 1061-1072.e8. DOI: 10.1016/j.cgh.2018.09.051.
[45]	BLAHO M, DÍTĚ P, KUNOVSKÝ L, et al. Autoimmune pancreatitis-An ongoing challenge[J]. Adv Med Sci, 2020, 65(2): 403-408. DOI: 10.1016/j.advms.2020.07.002.
[46]	MASAMUNE A, NISHIMORI I, KIKUTA K, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis[J]. Gut, 2017, 66(3): 487-494. DOI: 10.1136/gutjnl-2016-312049.